Revelation Biosciences (REVB) Treasury Shares (2020 - 2026)

Revelation Biosciences (REVB) posted quarterly Treasury Shares of $248124.0 for Q4 2025, up 263861.7% quarter-over-quarter from $94.0 in Q3 2024.

Revelation Biosciences (REVB) Treasury Shares (2020 - 2026) Analysis & Trends

Revelation Biosciences (REVB) has reported Treasury Shares for 6 consecutive years, with $248124.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Treasury Shares changed N/A year-over-year to $248124.0; the TTM figure through Dec 2025 stood at $248124.0 (changed N/A YoY), while the FY2025 annual figure was $248124.0, changed N/A from the prior year.
Treasury Shares climbed to $248124.0 in Q4 2025 per REVB's latest filing, from $94.0 in the prior quarter.
Across five years, Treasury Shares topped out at $7.3 million in Q2 2021 and bottomed at $94.0 in Q4 2023.
Historically, Treasury Shares has averaged $1.3 million across 5 years, with a median of $2085.5 in 2023.
Annual changes were most pronounced in 2023 — Treasury Shares tumbled 99.36% — and 2024, when it tumbled 94.25%.
Revelation Biosciences' Treasury Shares stood at $7.3 million in 2021, then tumbled by 99.9% to $7290.0 in 2022, then sank by 98.71% to $94.0 in 2023, then changed by 0.0% to $94.0 in 2024, then surged by 263861.7% to $248124.0 in 2025.
Business Quant data shows REVB's Treasury Shares at $248124.0 in Q4 2025, $94.0 in Q3 2024, and $94.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Revelation Biosciences	4.17 Mn	-7.33 Mn	-	-

Download Data